PT - JOURNAL ARTICLE AU - Christopher L. Shaffer AU - Mithat Gunduz AU - Renato J. Scialis AU - Annie F. Fang TI - Metabolism and Disposition of a Selective α<sub>7</sub> Nicotinic Acetylcholine Receptor Agonist in Humans AID - 10.1124/dmd.106.014449 DP - 2007 Jul 01 TA - Drug Metabolism and Disposition PG - 1188--1195 VI - 35 IP - 7 4099 - http://dmd.aspetjournals.org/content/35/7/1188.short 4100 - http://dmd.aspetjournals.org/content/35/7/1188.full SO - Drug Metab Dispos2007 Jul 01; 35 AB - The metabolism and disposition of N-(3R)-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide (1), an α7 nicotinic acetylcholinergic receptor agonist, were elucidated in humans (4 female, 4 male; all white) after an oral dose of [3H]1. Overall, 1 was well tolerated, with &gt;94% of administered radioactivity excreted renally by 48 h postdose; lyophilization of all urine and plasma samples confirmed 3H stability within [3H]1. Across genders, 1 underwent low-to-moderate oral clearance comprising both renal (67%) and metabolic (33%) components, with the biotransformation of 1 occurring predominantly via oxidation of its furanopyridine moiety to carboxylic acid 2, and minimally by modification of its quinuclidine nitrogen to N-oxide 4 or N-glucuronide M5. Experiments using human in vitro systems were undertaken to better understand the enzyme(s) involved in the phase 1 biotransformation pathways. The formation of 2 was found to be mediated by CYP2D6, a polymorphically expressed enzyme absent in 5 to 10% of white people, whereas the generation of 4 was catalyzed by CYP2D6, FAD-containing monooxygenase 1 (FMO1), and FMO3. It is of interest that, although no overall gender-related differences in excretory routes, mass recoveries, pharmacokinetics, or metabolite profiles of 1 were evident, the observation of one of eight subjects (13%) showing disparate (relative to all other volunteers) systemic exposures to 1, and urinary and plasma quantitative profiles nearly devoid of 2 with the highest levels of 1, seem consistent with both the identification of CYP2D6 as the only major recombinant cytochrome P450 transforming 1 to 2 and the demographics of white CYP2D6 poor metabolizers. Data also reported herein suggest that 4 is generated predominantly by renal FMO1 in humans. The American Society for Pharmacology and Experimental Therapeutics